Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Profit After Tax (2016 - 2025)

Ultragenyx Pharmaceutical has reported Profit After Tax over the past 10 years, most recently at -$128.6 million for Q4 2025.

  • Quarterly Profit After Tax rose 3.49% to -$128.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$575.0 million through Dec 2025, down 1.05% year-over-year, with the annual reading at -$575.0 million for FY2025, 1.05% down from the prior year.
  • Profit After Tax was -$128.6 million for Q4 2025 at Ultragenyx Pharmaceutical, up from -$180.4 million in the prior quarter.
  • Over five years, Profit After Tax peaked at -$73.0 million in Q3 2021 and troughed at -$245.1 million in Q3 2022.
  • The 5-year median for Profit After Tax is -$143.6 million (2021), against an average of -$145.6 million.
  • Year-over-year, Profit After Tax crashed 583.62% in 2021 and then skyrocketed 34.87% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$122.5 million in 2021, then fell by 23.99% to -$151.8 million in 2022, then grew by 18.63% to -$123.6 million in 2023, then decreased by 7.81% to -$133.2 million in 2024, then grew by 3.49% to -$128.6 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Profit After Tax are -$128.6 million (Q4 2025), -$180.4 million (Q3 2025), and -$115.0 million (Q2 2025).